RT Journal Article
SR Electronic
T1 Are rare heterozygous <em>SYNJ1</em> variants associated with Parkinson’s disease?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.29.24307986
DO 10.1101/2024.05.29.24307986
A1 Senkevich, Konstantin
A1 Parlar, Sitki Cem
A1 Chantereault, Cloe
A1 Yu, Eric
A1 Ahmad, Jamil
A1 Ruskey, Jennifer A.
A1 Asayesh, Farnaz
A1 Spiegelman, Dan
A1 Waters, Cheryl
A1 Monchi, Oury
A1 Dauvilliers, Yves
A1 Dupré, Nicolas
A1 Miliukhina, Irina
A1 Timofeeva, Alla
A1 Emelyanov, Anton
A1 Pchelina, Sofya
A1 Greenbaum, Lior
A1 Hassin-Baer, Sharon
A1 Alcalay, Roy N.
A1 Gan-Or, Ziv
YR 2024
UL http://medrxiv.org/content/early/2024/06/01/2024.05.29.24307986.abstract
AB Previous studies have suggested that rare biallelic SYNJ1 mutations may cause autosomal recessive parkinsonism and Parkinson’s disease (PD). Our study explored the impact of rare SYNJ1 variants in non-familial settings, including 8,165 PD cases, 818 early-onset PD (EOPD, &lt;50 years) and 70,363 controls. Burden meta-analysis using optimized sequence Kernel association test (SKAT-O) revealed an association between rare nonsynonymous variants in the Sac1 SYNJ1 domain and PD (Pfdr=0.040). Additionally, a meta-analysis focusing on patients with EOPD demonstrated an association between all rare SYNJ1 variants and PD (Pfdr=0.029). Rare SYNJ1 variants may be associated with sporadic PD, and more specifically with EOPD.Competing Interest StatementZGO received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Ono Therapeutics, Denali, Handl Therapeutics, Neuron23, Bial Biotech, Bial, UCB, Capsida, Vanqua bio, Congruence Therapeutics, Takeda, Jazz Pharmaceuticals, Guidepoint, Lighthouse and Deerfield.Funding Statementhttps://github.com/gan-orlab/SYNJ1Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All local IRBs approved the protocols and informed consent was obtained from all individual participants before entering the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data relevant to this study are included within thearticle and the accompanying supplementary files.